Log in to save to my catalogue

Phase IV postmarketing surveillance study shows continued efficacy and safety of Stempeucel in patie...

Phase IV postmarketing surveillance study shows continued efficacy and safety of Stempeucel in patie...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_d9172901775d4f848f334111134a5c7c

Phase IV postmarketing surveillance study shows continued efficacy and safety of Stempeucel in patients with critical limb ischemia due to Buerger's disease

About this item

Full title

Phase IV postmarketing surveillance study shows continued efficacy and safety of Stempeucel in patients with critical limb ischemia due to Buerger's disease

Publisher

Hoboken, USA: John Wiley & Sons, Inc

Journal title

Stem cells translational medicine, 2021-12, Vol.10 (12), p.1602-1613

Language

English

Formats

Publication information

Publisher

Hoboken, USA: John Wiley & Sons, Inc

More information

Scope and Contents

Contents

Buerger's disease or thromboangiitis obliterans is a type of obstructive vascular diseases categorized as vasculitis and usually present in 95% of young smoker men. The main pathogenetic mechanism is interplay between immune system and inflammation. Earlier our phase II study has shown that Stempeucel is safe when injected at 2 million cells/kg bod...

Alternative Titles

Full title

Phase IV postmarketing surveillance study shows continued efficacy and safety of Stempeucel in patients with critical limb ischemia due to Buerger's disease

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_d9172901775d4f848f334111134a5c7c

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_d9172901775d4f848f334111134a5c7c

Other Identifiers

ISSN

2157-6564,2157-6580

E-ISSN

2157-6580

DOI

10.1002/sctm.21-0197

How to access this item